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Abstract
Although several successful clinical trials in the last 2-3 years have been greeted with enthusiasm
by intensivists, severe sepsis and septic shock still have increasing incidence and more or less
unchanged mortality. Within the last few years, the progress in sepsis research covering definitions,
epidemiology, pathophysiology, diagnosis, and standard and adjunctive therapy as well as general
measures such as treatment bundles is encouraging. In this report, a small selection of recent
publications, focusing on the current discussion of activated protein C as well as the relevance of the
Surviving Sepsis Campaign bundle therapy, is presented and the possible impact on clinical routine is
discussed.
Introduction and context
Sepsis is a leading cause of hospital mortality in adult
patients, and the incidence is increasing [1]. There is
considerable variation between countries, with a strong
correlation between the frequency of sepsis and intensive
care unit (ICU) mortality rates [2]. In a prospective study
of 3877 patients in 454 German ICUs, the prevalence of
sepsis was 12.4% [3]. The prevalence of severe sepsis,
defined as sepsis associated with organ dysfunction, was
11.0%. Of those with severe sepsis, nearly half had septic
shock, defined as sepsis with hypotension despite
adequate fluid replacement. The incidence of severe
sepsis was estimated to be 76-110 cases/year per 100,000
inhabitants. Outcome data revealed ICU and hospital
mortality rates of 48.4% and 55.2%, respectively [3].
Patients surviving sepsis have a lower quality of life than
the age- and sex-adjusted population as much as 1.5
years later [4]. The economic burden of severe sepsis is
immense. The daily cost is estimated to be 1090 euros
(approximately USD $1600), and the overall costs per
hospital stay are estimated to be 2-fold to 11-fold higher
than the general cost per patient [5].
Currently available strategies for the management of
sepsis patients include timely patient identification and
diagnosis, rapid identification of causative organisms,
appropriate and early antimicrobial therapy, improved
ventilatory techniques, goal-directed hemodynamic sup-
port, targeted immunological therapy, glycemic control,
appropriate nutrition, effective supportive therapies, and
patient management by highly qualified clinicians and
nursing staff. These multifaceted approaches to patient
management, the use of evidence-based methods, and
the adoption of incremental, goal-oriented strategies are
vital to combat this complex, aggressive, and increasingly
prevalent condition.
Recent advances
Pathophysiology
Sepsis is a complex phenomenon that remains incomple-
tely understood. Infectious pathogens possess unique
structural components called pathogen-associated mole-
cular patterns; examples include lipopolysaccharide in
Gram-negative bacteria and peptidoglycan in Gram-
positive bacteria [6]. These molecules bind to host cell
receptors known as ‘pattern recognition receptors’,w h i c h
include the cell-surface Toll-like receptors and several
types of cytoplasmic receptors [7]. Receptor binding
results in the activation of intracellular signaling pathways
that lead to a variety of responses, including increased
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adhesion molecule expression, stimulation of humoral
and cell-mediated immune responses, and activation of
vascular endothelial cells. A detailed discussion of the
pathogenesis of sepsis is beyond the scope of this article,
but the subject has been addressed in a number of recent
reviews [8-11].
An important feature of the pathophysiology of sepsis is
the development of a procoagulant state [12]. Inflamma-
tory cytokines activate the coagulationcascade and inhibit
fibrinolysis. In turn, components of the coagulation and
fibrinolytic systems have proinflammatory effects. Dis-
seminated intravascular coagulation, one of the most
feared complications of sepsis, is a manifestation of the
dysregulation of coagulation seen in this disorder [12].
Activated protein C
In severe sepsis, treatment of the underlying cause of
infection requires early and meticulous attention to
source control, including the use of antimicrobial agents
and, where appropriate, surgical drainage. Physiological
support of organ dysfunction with inotropes, mechanical
ventilation, and renal replacement therapy should be
instituted depending upon the individual clinical cir-
cumstances. Specific drugs such as corticosteroids are
broadly used, although the benefit of such therapy
remains uncertain [13,14].
Protein C is a soluble, vitamin K-dependent, plasma
serine protease that plays a central role in endogenous
anticoagulation [15]. The activated form is generated
when thrombin, bound to the cofactor thrombomodu-
lin, interacts with and cleaves the zymogen protein C.
Activated protein C (APC) is a potent anticoagulant and
profibrinolytic enzyme capable of inactivating clotting
factorsVaandVIIIaandplasminogenactivatorinhibitor1.
The exact role of APC in the treatment of septic shock is
eagerly debated, and a recent review from our group gives
an overview [15].
Unexpected reversal of refractory septic shock with APC
was recently described [16]. The 23 patients included in
this observational study had a 100% risk of death,
according to a score based on the response to early
continuous veno-venous hemodiafiltration. The actual
28-day mortality rate of the 23 patients who received
APC was only 39% and was associated with a decrease
in the magnitude of lactic acidosis and the dose of
norepinephrine required. In a double-blind randomized
placebo-controlled trial, the safety and efficacy of
extended APC treatment were evaluated in 64 ICUs in
nine countries. Patients (n = 193) received APC for a
maximum of 3 days. However, extended APC treatment
was not associated with reductions in day-28 all-cause
mortality or in-hospital mortality or with an increase in
serious adverse events [17]. Heparin used concomitantly
with APC was explored in a large randomized study, and
no heparin effect on mortality was observed [18]. Further
analyses revealed that the coadministration of APC with
low-dose heparin in patients with severe sepsis did not
increase the incidence of serious bleeding. Fewer
ischemic strokes in the heparin group suggest that
heparin cessation should be avoided during APC
infusion [18]. Finally, recent observational data from a
large international sepsis registry demonstrated a bene-
ficial effect of the treatment with APC [19].
Implementing treatment bundles
In 2002, the Surviving Sepsis Campaign (SSC) was
launched. This international group of investigators
developed evidence-based guidelines through a formal
and transparent process. The initial guidelines were
published in 2004, and an updated version was
published in 2008 [20]. The development and publica-
tion of guidelines often do not lead to changes in clinical
behavior, and guidelines are rarely, if ever, integrated
into bedside practice in a timely fashion [21]. Recogniz-
ing that implementing guidelines presents a significant
challenge, the SSC set out to develop and evaluate a
multifaceted model to change bedside practice for
patients with severe sepsis and septic shock by the
definition of ‘sepsis resuscitation bundles’ as well as
‘sepsis management bundles’ [22]. A central part of that
program was an international registry that providers
could use to monitor the performance of their institution
and to recruit and enter patients. A Spanish cohort study
demonstrated significant benefit after implementing
these bundles [23]. In January 2010, the first analysis
of the worldwide registry data described the global
initiative and its implementation and reported its impact
on process improvement and patient outcomes [24].
Data from 15,022 subjects at 165 sites were analyzed to
determine the compliance with bundle targets and
association with hospital mortality. Compliance with
the entire resuscitation bundle increased linearly from
10.9% in the first site quarter to 31.3% by the end of
2 years (P < 0.0001). Unadjusted hospital mortality
decreased from 37% to 30.8% over 2 years (P = 0.001).
The adjusted odds ratio for mortality improved the
longer a site was in the SSC, resulting in adjusted
absolute decreases of 0.8% per quarter and 5.4% over
2 years (95% confidence interval 2.5-8.4%) [24].
Implications for clinical practice
The management of sepsis in hospitals is significantly
better today than it was 10 years ago. However, sepsis-
associated mortality rates remain unacceptably high, and
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be embraced further still. The recent improvement in
outcomes of patients with severe sepsis and septic shock
has been characterized by the successive introduction of
multiple interventions and therapies, which is an
ongoing process. The results of the aforementioned
studies [23,24] demonstrate that the use of a multi-
faceted performance improvement initiative was success-
ful in changing sepsis treatment behavior as evidenced
by a significant increase in compliance with sepsis
performance measures. This compliance was associated
with a significant reduction in hospital mortality in
patients with severe sepsis and septic shock over the
duration of the 2-year study, but the study design does
not allow us to say, with certainty, whether this was due
to some or all bundle elements, increased awareness of
severe sepsis, or other unrelated factors [24]. There are
still many unanswered questions – including the
mortality trend in hospitals that have not implemented
the bundles and confirmation of which components of
the bundles reduce mortality – that could provide
direction for future research. The results of this study
should encourage similar efforts to implement guide-
lines and treatment protocols as a means to improve
outcomes. Finally, the importance of the wholehearted
involvement of the entire health care team and the
provision of strong public and political support in
achieving these objectives cannot be stressed enough.
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